| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(202)_ICD10(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis | 1684 | |
| REIMB | REIMB_KELA(202)_ICD10(M058) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Other seropositive rheumatoid arthritis | 1671 | |
| REIMB | REIMB_KELA(313)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Other seropositive rheumatoid arthritis | 978 | |
| REIMB | REIMB_KELA(281)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Other seropositive rheumatoid arthritis | 885 | |
| REIMB | REIMB_KELA(313)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis | 705 | |
| REIMB | REIMB_KELA(281)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis | 575 | |
| REIMB | REIMB_KELA(202)_ICD10(M059) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis, unspecified | 176 | |
| REIMB | REIMB_KELA(291)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 85 | |
| REIMB | REIMB_KELA(3006)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 74 | |
| REIMB | REIMB_KELA(293)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 58 | |
| REIMB | REIMB_KELA(291)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 37 | |
| REIMB | REIMB_KELA(313)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis, unspecified | 37 | |
| REIMB | REIMB_KELA(3005)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 34 | |
| REIMB | REIMB_KELA(293)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 30 | |
| REIMB | REIMB_KELA(281)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis, unspecified | 29 | |
| REIMB | REIMB_KELA(3006)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 25 | |
| REIMB | REIMB_KELA(3005)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 19 | |
| REIMB | REIMB_KELA(202)_ICD9(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 9 | |
| REIMB | REIMB_KELA(313)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Felty's syndrome | 6 | |
| REIMB | REIMB_KELA(281)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Felty's syndrome | 5 |